Sign In
Buy ASND
$265.22
-5.23 (-1.93%)
At Close: Jul 13, 2026
Why Crinetics Stock Soared 99% This Week
01:29pm, Thursday, 09'th Jul 2026
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
14 value stocks of companies primed for rapid growth through 2028
12:10pm, Wednesday, 01'st Jul 2026
Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly T
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
04:01pm, Friday, 26'th Jun 2026
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russel
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
11:45am, Friday, 26'th Jun 2026
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
04:01pm, Thursday, 25'th Jun 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
04:00pm, Saturday, 13'th Jun 2026
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with T
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
09:55am, Friday, 12'th Jun 2026
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Among the top contributors to relati
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
04:01pm, Thursday, 11'th Jun 2026
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatme
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
04:59pm, Monday, 08'th Jun 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achon
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
12:16am, Thursday, 28'th May 2026
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth,
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
01:01am, Saturday, 09'th May 2026
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma Reports First Quarter 2026 Financial Results
07:30am, Thursday, 07'th May 2026
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ®
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age a
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
04:01pm, Thursday, 30'th Apr 2026
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thur
